United States Patent 8,733,341 Landscape: What the Claims Cover, Claim Scope Boundaries, and How Competitors Can Design Around
US Patent 8,733,341 (atomizer/portable inhaler) is a mechanical metering and nozzle-rinsing concept: a conveying element (conveying tube) moves in a preliminary “tensioning” stroke to deliver a small preliminary amount that rinses the nozzle, then moves in a main stroke to deliver a metered full dose for atomization. The claims also lock that conveying element in a tensioning position, with release by a manual locking element, and impose specific quantitative ranges for the preliminary amount and preliminary stroke in dependent claims.
From an IP-risk perspective, the actionable infringement hooks are (i) the “preliminary amount” delivered before each metered full dose (or on each tensioning) and used for nozzle rinsing, (ii) the two-stage conveying movement (preliminary to tensioning, then main movement to deliver full dose), and (iii) the spring-countered drive with gear/manual over-tensioning back to tensioning. Design-arounds that eliminate the nozzle-rinsing preliminary dose, change the dosing sequence so no preliminary “rinsing” aliquot is delivered prior to full dose, or replace the two-stage motion/over-tensioning-spring architecture are the highest-leverage.
US Patent 8,733,341 claim construction: What is the core invention and what elements must be present?
Core invention in one sentence: An inhaler atomizer that meters discrete full doses via a conveying tube driven by spring mechanics, while delivering a substantially smaller preliminary aliquot before each full dose to rinse the nozzle, accomplished via a preliminary movement to a tensioning position followed by a main movement to atomize the full dose.
What the independent claim 1 requires (element-by-element)
Claim 1 recites an atomizer comprising:
- A fluid reservoir/container (container 3) holding the fluid (2).
- A nozzle for delivery and atomization (nozzle 12).
- Metered individual full-doses: the fluid is delivered in metered “individual full-doses” through the nozzle.
- A conveying element as a conveying tube (9) that is movable.
- Two-stage motion tied to tensioning:
- (i) preliminary movement to a tensioning position to deliver a preliminary amount.
- then (ii) main movement to deliver the full-dose for actual delivery and atomization.
- Spring-countered mobility with an over-tensioning mechanism:
- the conveying element is movable counter to spring force by at least one of:
- a gear (20), and
- manual actuation of the atomizer into an over-tensioning position.
- from the over-tensioning position, the conveying element is moved by spring force into the tensioning position.
- Nozzle rinsing by the preliminary amount:
- the preliminary amount is substantially less than the full dose and rinses the nozzle, and is delivered:
- before delivery of each metered full-dose or
- on each tensioning of the atomizer.
Infringement consequence: A product that meters full doses but does not deliver a preliminary aliquot for nozzle rinsing, or does not include a preliminary-to-tensioning step before the full-dose delivery, will have a strong claim-interpretation path to non-infringement.
Claim 11 parallels claim 1 as a method claim
Claim 11 uses the same dosing mechanics: moving a conveying tube in preliminary movement to tensioning (preliminary aliquot), then main movement for delivery/atomization of the full dose, with over-tensioning against spring force and nozzle rinsing by the preliminary aliquot.
Method claims track the same design features: devices that perform all steps (as used) implicate method claim coverage even if structure is different.
Dependent claim boundaries that narrow the scope
Dependent claims add specific limitations that can reduce infringement coverage but also define the inventor’s “sweet spot”:
- Claim 2: preliminary amount between 0.5 to 3.0 microliters.
- Claim 3: preliminary amount is either:
- 1 to 10% of full dose, or
- at least five times the nozzle volume.
- Claim 4: preliminary movement and main movement are carried out exclusively by spring force.
- Claim 5: preliminary stroke 0.2 to 1 mm.
- Claim 6: a locking element securing the conveying element in tensioning position, manually moved to release.
- Claim 7: fluid contains a solvent.
- Claim 8 and claim 10: inhalable formulation list of actives (broad therapeutic categories) and any combination.
- Claim 9: portable inhaler for medicinal aerosol therapy.
Practical claim-scope effect: If a competitor’s architecture meets the independent claim’s sequence/mechanics but uses a different preliminary amount outside the microliter/percent/nozzle-volume ranges, they may avoid dependent-claim infringement while still risking independent-claim coverage unless the independent claim interpretation anchors “substantially less” to those ranges.
How do “preliminary amount” and “rinses the nozzle” control infringement risk?
Key two-word pinch points: “substantially less” and “rinses the nozzle.”
“Substantially less than the individual metered full-dose”
This is an elastic term, but the dependent claims supply numerical anchors. Even without those dependent claims being met, courts often treat explicit embodiments as informative for claim meaning.
High-risk range: The dependent claims suggest the preliminary aliquot is intended to be in the microliter scale and a small fraction of full dose (0.5–3.0 µL; 1–10%; or ≥ five times nozzle volume). A device delivering a preliminary aliquot in that order of magnitude is more likely to be argued as “substantially less.”
“Rinses the nozzle”
“Rinses” is functional language. It does not require a specific cleaning chemistry, but it does require the preliminary amount to have a purpose/effect of clearing residuals in or at the nozzle flow path such that it conditions subsequent atomization of the full dose.
Design-around pathways with the strongest non-infringement posture:
- Eliminate any pre-dose aliquot delivered through the nozzle before the main dose.
- Deliver the preliminary aliquot into a different region that does not interact with the nozzle flow path used for atomization.
- Use a different nozzle conditioning strategy (for example, a static anti-sticking lining) rather than a preliminary fluid flush delivered immediately prior to each full dose.
What is the “two-stage movement to a tensioning position” architecture and how is it used in claim scope?
The conveying tube moves:
- Preliminary movement to a tensioning position while delivering the preliminary aliquot.
- Main movement after the tensioning stage to deliver the metered full-dose and atomize.
Spring-countered over-tensioning mechanism
Claim 1 requires that the conveying element moves counter to spring force by at least one of:
- a gear mechanism, and/or
- manual actuation to an over-tensioning position,
and then moves by spring force into the tensioning position.
What this implies for competitors: A spring-driven single-step metering motion is likely not enough. A two-step dosing sequence that ties a first aliquot to “tensioning” followed by a second movement for full dose is the architectural hallmark.
Gear/manual over-tensioning: Claim 1 is “at least one of” gear or manual over-tensioning. A design that uses neither could be harder to argue within claim 1, but the independent claim still requires “movable counter to spring force” which typically is a spring-countered architecture anyway.
How do the quantitative dependent claims narrow the allowable preliminary flush design?
Dependent claims map design parameters that can be used in both enforcement and freedom-to-operate (FTO) triage.
| Claim |
Parameter |
Range / Condition |
IP role |
| 2 |
Preliminary volume |
0.5 to 3.0 µL |
Converts “substantially less” into a measured range |
| 3 |
Preliminary volume relation |
1 to 10% of full dose, or ≥ 5× nozzle volume |
Provides alternative numeric anchors |
| 5 |
Preliminary stroke |
0.2 to 1 mm |
Constrains mechanical displacement during preliminary step |
| 4 |
Drive mode |
preliminary + main exclusively by spring force |
Eliminates hybrid actuation designs |
| 6 |
Locking element |
locks conveying element at tensioning position; manual release |
Requires the locking architecture |
Competitor leverage: If a competitor’s device uses the same two-stage logic but chooses preliminary flush volumes/strokes outside these ranges, they may reduce dependent-claim exposure. But independent claim risk remains unless claim construction still reads the “substantially less” term narrowly in light of the dependent embodiments.
What formulations are covered, and does it create a separate IP lane or just cover-the-categories?
Claims 8 and 10 list inhalable medicaments across multiple therapeutic classes (anticholinergics, betamimetics, steroids, PDE4 inhibitors, LTD4 antagonists, EGFR kinase inhibitors, antiallergics, ergot derivatives, triptans, CGRP antagonists, PDE5 inhibitors, and combinations).
These are ingredient/category limitations. They can create a second layer of risk for device partners if the same mechanical dosing architecture is used with those active ingredients.
Scope reality: If a competitor’s device architecture matches the mechanical claims, using an active outside the listed categories can be a pathway to avoid the specific dependent-claim constraints. But independent mechanical coverage does not depend on the particular formulation categories.
Orange Book status, FDA pathway, and exclusivity implications: what can be concluded from the claim text alone?
No information provided. The claim set does not identify a specific FDA-listed drug product, reference product, application number, or dosage form (other than “portable inhaler”). Without that, no Orange Book listing, regulatory exclusivity timeline, or Paragraph IV pathway can be reliably assigned to US 8,733,341.
Accordingly, any exclusivity analysis for FDA would be unsupported.
Patent estate mapping for US 8,733,341: what related claims and continuations typically exist, and where to look for them
No sufficient bibliographic data provided (publication number, filing date, assignee, inventor names, priority applications, continuation/child patents). Without that, a complete landscape for “the scope and claims and patent landscape” cannot be constructed to a professional standard.
However, the claim content suggests the likely landscape shape:
- a cluster around metered-dose portable inhaler atomizers,
- mechanical spring-driven dosing with two-stage delivery and nozzle rinsing,
- dependent narrowings on preliminary volume, preliminary stroke, locking elements, and drive mode,
- and formulation-specific dependent claims tying the same hardware platform to particular therapeutic agent categories.
A defensible landscape analysis requires the patent’s full legal bibliographic record and the assignee portfolio around the same priority. That record is not included.
How would a competitor design around US 8,733,341? (Claim-specific design-around checklist)
Highest-probability non-infringement edits
-
Remove the nozzle-rinsing preliminary aliquot
- Deliver only full-dose metering per actuation.
- Any “priming” that does not rinse the nozzle prior to full-dose atomization is a key divergence.
-
Change dosing sequence
- If preliminary movement to tensioning occurs, ensure no fluid is delivered through the nozzle that rinses the nozzle before full-dose delivery.
- Alternatively, reposition preliminary delivery so it is not delivered through the nozzle path used for the full dose.
-
Eliminate the two-stage preliminary-to-tensioning then main delivery structure
- Use a single continuous displacement or a different actuator that does not define a tensioning position tied to a preliminary aliquot delivered before the full dose.
-
Avoid the over-tensioning then spring release into tensioning
- If no over-tensioning position exists and the conveying element motion is not spring-force governed in the claim’s sequence, the independent claim can be weakened.
Dependent-claim-specific “narrow” design-around
Even if the independent claim is arguably met, competitors can reduce dependent-claim risk by altering:
- preliminary volume away from 0.5–3.0 µL and away from the 1–10% and ≥5× nozzle volume relationships,
- preliminary stroke away from 0.2–1 mm,
- drive mode so preliminary and main movements are not exclusively by spring force,
- locking architecture so there is no locking element that secures the conveying tube in tensioning position and is manually released.
Litigation and IPR landscape: what can be stated from the provided information?
No litigation records, PTAB filings, or enforcement actions are provided. Without docket data, party names, or decision documents, no accurate status assessment can be produced.
Key Takeaways
- US 8,733,341 centers on a mechanical two-stage metering and nozzle-rinsing concept: a conveying tube moves to a tensioning position delivering a small preliminary aliquot, then moves in a main movement delivering a metered full dose for atomization.
- The independent claim’s infringement core is the combination of:
(i) preliminary aliquot substantially less than the full dose delivered before each full dose or on each tensioning, (ii) nozzle rinsing, and (iii) spring-countered, over-tensioning-to-tensioning mechanics using the conveying tube.
- Dependent claims narrow key parameters: preliminary volume (µL and percent), preliminary stroke (mm), spring-only motion, and the presence of a locking element at tensioning.
- Competitors can target non-infringement primarily by eliminating the nozzle-rinsing preliminary flush or altering the dosing sequence and mechanics so no claim element combination is met.
FAQs
-
What does “substantially less” likely mean in practice for the preliminary amount vs the full dose?
Dependent ranges (0.5–3.0 µL; 1–10%; or ≥5× nozzle volume) provide the clearest numerical anchors for interpretation.
-
Does the independent claim require a gear or is manual over-tensioning enough?
Claim 1 allows “at least one of” gear or manual actuation into an over-tensioning position.
-
Can a device that flushes the nozzle after the full dose avoid claim 1?
The claim ties nozzle rinsing to the preliminary amount delivered before each full dose or on each tensioning; after-dose flushing diverges from the recited timing.
-
If a device has a preliminary movement to tensioning but delivers no fluid before full dose, is it covered?
Claim 1 requires the preliminary movement to deliver a preliminary amount that rinses the nozzle before full-dose delivery.
-
Do the formulation-dependent claims limit mechanical infringement?
The independent mechanical claim is formulation-agnostic; formulation categories matter for dependent claim coverage only.
References
- User-provided claim text for US 8,733,341 (claims 1–16).
